Widespread errors in 'proofreading' cause inherited blindness
(Newcastle University) Research has shown that mistakes in 'proofreading' the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) with splicing factor defects, which affects up to 2.5 million people worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 12, 2018 Category: International Medicine & Public Health Source Type: news

Bascom Palmer treats first US patient in Nightstar gene therapy
(University of Miami Miller School of Medicine) A Puerto Rican patient with X-linked retinitis pigmentosa (XLRP) is hoping to save his vision after an innovative gene therapy procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. On August 23, Julio Adorno Nieves, 23, became the first US patient to be given new genes for his inherited blinding condition in a worldwide Nightstar Therapeutics clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2018 Category: International Medicine & Public Health Source Type: news

Researchers find potential new gene therapy for blinding disease
Scientists funded by NIH preserve vision in dogs with a disease similar to retinitis pigmentosa in humans. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 20, 2018 Category: American Health Source Type: news

Lessons from flies: genetic diversity impacts disease severity
(University of Utah Health) New research offers clues as to why some diseases are highly variable between individuals. The phenomenon is apparent in retinitis pigmentosa, a condition that causes the light-sensing cells in the eye to degenerate. By analyzing thousands of flies, scientists at University of Utah Health found that variation in a background gene, called Baldspot, can make a difference in severity of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 6, 2018 Category: International Medicine & Public Health Source Type: news

UCI researcher receives CIRM funding for stem cell-based retina therapy to treat blindness
(University of California - Irvine) California Institute of Regenerative Medicine funding to support continued development of a stem cell-based therapy for vision-robbing eye diseases, such as retinitis pigmentosa and macular degeneration. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 26, 2018 Category: Biology Source Type: news

Gene therapy that restores vision in dogs may help humans, too
(Michigan State University) A Michigan State University veterinary ophthalmologist has modified a gene therapy that reverses blindness in dogs that have a certain form of a disease known as progressive retinal atrophy, or PRA, and is now looking to advance the treatment for human use. Simon Petersen-Jones in the College of Veterinary Medicine has received a five-year, $8.2 million grant from the National Institutes of Health to further the therapy for people who have a type of retinitis pigmentosa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2018 Category: International Medicine & Public Health Source Type: news

Genome surgery for eye disease moves closer to reality
(American Academy of Ophthalmology) Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2018 Category: International Medicine & Public Health Source Type: news

Strategy prevents blindness in mice with retinal degeneration
(Duke University Medical Center) New research published in Nature Communications outlines a strategy that in mouse models significantly delayed the onset of blindness from inherited retinal degeneration such as retinitis pigmentosa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news

Vitamin A Appears Helpful in Pediatric Retinitis Pigmentosa
MONDAY, April 2, 2018 -- For children with retinitis pigmentosa, vitamin A supplementation is associated with slower loss of cone electroretinogram amplitude, according to a study published online March 29 in JAMA Ophthalmology. Eliot L. Berson,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2018 Category: Pharmaceuticals Source Type: news

Vitamin A Slows Progression of Retinitis Pigmentosa in Kids
(MedPage Today) -- Now the question is how (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 30, 2018 Category: Pediatrics Source Type: news

Medicare adds coverage in 3 states for Second Sight ’ s Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today that Medicare Administrative Contractor Palmetto GBA is now providing coverage for the Argus II retinal prosthesis system and its associated surgical procedures The Sylmar, Calif.-based company said the approval expands coverage to Alabama, Georgia and Tennessee, bringing the total states covered for the device up to 31, as well as two territories and the District of Columbia. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light ...
Source: Mass Device - March 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Source Type: news

Second Sight Medical enters Singapore market, touts 1st procedure in region
Second Sight Medical (NSDQ:EYES) said today it entered the Singapore market with its Argus II retinal prosthesis system through its regional exclusive distribution partner Mandarin Opto-Medic. The Sylmar, Calif.-based company said that its Argus II systems have been used in their first commercial procedure in the region, implanted last month in a 62-year-old patient with retinal degeneration at the Singapore National Eye Center by Dr. Edmund Wong and Dr. Laurence Lim with supervision from Dr. Emin Özmert. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the...
Source: Mass Device - February 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Source Type: news

Second Sight touts 1st-in-human Orion cortical implant
Second Sight Medical (NSDQ:EYES) today announced the first trial implantation of its Orion cortical visual prosthesis system and updated on implantations of its Argus device and enrollment in an upcoming study. The first implantation procedure was performed late last month by Dr. Nader Pouratian at the Ronald Reagan UCLA Medical Center, the Sylmar, Calif.-based company said, as part of an FDA-cleared feasibility trial it won approval to launch last November. The Orion cortical visual prosthesis system is designed to convert images captured by a miniature video camera, mounted on a patient’s glasses, into a ...
Source: Mass Device - February 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Second Sight Source Type: news

GenSight to launch trial of gene therapy, visual stimulation device combo in UK
The UK’s Medicines and Healthcare Regulatory Agency has approved GenSight Biologics‘ (EPA:SIGHT) application to combine gene therapy and a wearable optronic visual stimulation device in patients with retinitis pigmentosa. The first-in-man Phase I/II trial is designed to study the safety and tolerability of GenSight’s GS030 combination therapy in three groups of three patients each. Get the full story at our sister site, Drug Delivery Business News. The post GenSight to launch trial of gene therapy, visual stimulation device combo in UK appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 10, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat gensightbiologics Source Type: news

Commonalities in late stages of inherited blinding diseases suggest targets for therapy
(University of Pennsylvania) In studying the late stages of disease in two different canine models of retinitis pigmentosa, a group of progressive and inherited blinding diseases, University of Pennsylvania researchers found commonalities, specifically involving the innate immune system. The findings point to potential new treatment options for the conditions. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 20, 2017 Category: Biology Source Type: news

Second Sight launches Argus retinal prosthesis in Iran
Second Sight Medical (NSDQ:EYES) said today it launched its Argus II retinal prosthesis system in Iran, facilitated through its exclusive distribution partner Arshia Gostar Darman. The Sylmar, Calif.-based company said that the system has been implanted in two patients in the country, with the procedures performed by Dr. Mohsen Farvadin at the Shiraz Pars Hospital and Khalili Hospital, Shiraz Medical Science University in 44-year old and 33-year old patients with retinitis pigmentosa. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining ...
Source: Mass Device - December 5, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Source Type: news

What is Usher Syndrome?
Discussion Over 7000 diseases are considered rare disorders according to the National Organization for Rare Disorders® (NORD, rarediseases.org). NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. They have information on about 1200 rare diseases on their website (https://rarediseases.org/for-patients-and-families/information-resources/rare-disease-information/). Hearing loss (HL) is not rare and is a common problem across the ages. It affects 360 million people worldwide which is about 5% of the population. There are many causes of hearing loss an...
Source: PediatricEducation.org - October 23, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Pixium Vision wins French approval for Prima sub-retinal implant study
Pixium Vision (EPA:PIX) said today it won approval from France’s regulatory agency to launch a feasibility clinical study of its next-gen Prima sub-retinal implant in patients with advanced dry age-related macular degeneration. The Prima system is a next-gen wireless implant with a micro photovoltaic chip designed to be implanted under the retina to convert pulsed near-infra-red invisible light received from external glasses with an integrated mini-camera into electrical signals transmitted to the brain through the optic nerve, the company said. The system is designed to treat retinal dystrophies with a foc...
Source: Mass Device - October 19, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Pixium Vision Source Type: news

Second Sight wins go-ahead for German Argus II study in better-sighted RP patients
This study has the potential to change the management of patients with RP and, if successful, greatly expand the patient population who can benefit from this treatment, and for whom the Argus II could be a solution,” Dr. Walter of Germany’s Universitätsklinikum Aachen said in a prepared statement. In July, Second Sight said its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia. See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif. The post...
Source: Mass Device - October 17, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Optical/Ophthalmic Regulatory/Compliance Second Sight Source Type: news

Single gene injected into eye reverses type of blindness
Breakthrough made by Oxford researchers in treating retinitis pigmentosa, which affects 20,000 Britons. A single gene injected into the back of the eye was found to restore vision. (Source: the Mail online | Health)
Source: the Mail online | Health - October 2, 2017 Category: Consumer Health News Source Type: news

Keeping Calm in the OR: Ophthalmology Times
(MedPage Today) -- Also, approaches to promote cone regeneration in retinitis pigmentosa (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 19, 2017 Category: American Health Source Type: news

Second Sight Medical enters Russian market
Second Sight Medical (NSDQ:EYES) said today it entered the Russian market, with the 1st patient treated with its Argus II Retinal Prosthesis System in Moscow. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the Sylmar, Calif.-based company said. The 1st implant was performed at the Federal State Institution & Clinical Research Center of the Federal Medico-Biological Agency at the end of June 2017 by a team of surgeons, with Dr. Paulo Stanga ...
Source: Mass Device - July 26, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic second-sight-medical Source Type: news

Second Sight Medical wins expanded CMS coverage for Argus II
Second Sight Medical (NSDQ:EYES) said today its Argus II retinal prosthesis system won expanded reimbursement coverage from the Centers for Medicare and Medicaid Services in 11 additional states and the District of Columbia. With the expansion, the Sylmar, Calif.-based company said it’s Argus II device is now reimbursable in 7 of the 12 Medicare Administrative Contractor jurisdictions, covering the device in a total of 28 states, 2 territories and D.C. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulse...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic second-sight-medical Source Type: news

Gene mutation linked to retinitis pigmentosa in Southwestern US Hispanic families
(University of Texas Health Science Center at Houston) Thirty-six percent of Hispanic families in the U.S. with a common form of retinitis pigmentosa got the disease because they carry a mutation of the arrestin-1 gene, according to a new study from researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2017 Category: International Medicine & Public Health Source Type: news

Boston man's bionic eye gives back sight to blind man
Anthony Andreottola, 56, was diagnosed with retinitis pigmentosa and was blind at 35 years old. The Boston man was finally able to see again with the help of a bionic eye surgery in 2015. (Source: the Mail online | Health)
Source: the Mail online | Health - June 16, 2017 Category: Consumer Health News Source Type: news

Bionic eye helps blind man see with "artificial vision"
A Boston man who lost his sight to the eye disease retinitis pigmentosa is getting a new look at the world with bionic eye technology. Paula Ebben of CBS Boston station WBZ reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 14, 2017 Category: Consumer Health News Source Type: news

Medford Man Receives Bionic Eye
MEDFORD (CBS) — After 20 years of darkness, there is light. It seems like science fiction, but a bionic eye implant is bringing a kind of sight to the blind. It’s not what you and I see, but for a small number of people, it’s making all the difference. “It’s not actual vision. It’s what they call artificial vision,” says Anthony Andreotolla, one of the first people to ever receive a bionic eye. Every day he puts on his gear, leaves his Medford home and rides the MBTA to his job in Downtown Crossing. Anthony Andreotolla wearing bionic eye (WBZ-TV) Andreotolla has retinitis pigm...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 13, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Bionic Eye Medford Paula Ebben Second Sight Source Type: news

Oxford robotic surgery, synthetic retina advances could help visually impaired
[Image from unsplash.com]The University of Oxford has recently had some major advances for treating the visually impaired. Surgeons at the university recently performed the world’s first operation inside the eye using robotics and a student created what the university says is the first synthetic retina. Ophthalmology professor Robert MacLaren and Nuffield Medical fellow Dr. Thomas Edwards performed eye surgery using a remotely controlled robot, lifting a membrane of the retina at the back right of the eye that was 1/100 mm thick. The surgery was performed on the Rev. Dr. William Beaver. Beaver’s surgery was per...
Source: Mass Device - May 12, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Optical/Ophthalmic Research & Development blindness MedTech retinitis pigmentosa Robotic Surgery Source Type: news

Student Creates First Synthetic Retina For Visually Impaired
Study could revolutionise bionic implant industry and development of less invasive technologies helping to treat degenerative eye conditions such as retinitis pigmentosa (Source: Disabled World)
Source: Disabled World - May 5, 2017 Category: Disability Tags: Visual Aid Products and Information Source Type: news

Second Sight shares drop on Q1 miss
Shares in Second Sight Medical (NSDQ:EYES) have dropped today after the medical device maker missed expectations on Wall Street with its 1st quarter results. The Sylmar, Calif-based company posted losses of $7.5 million, or 16¢ per share, on sales of $1 million for the 3 months ended March 31, seeing losses grow 29.8% while sales shrunk 4.2% compared with the same period during the prior year. Analysts on Wall Street were expecting to see losses per share of 14¢, which Second Sight medical came in just above. “With a focus on execution and our centers of excellence strategy, we had strong implant volume dur...
Source: Mass Device - May 4, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup second-sight-medical Source Type: news

Using CRISPR to reverse retinitis pigmentosa and restore visual function
Using the gene-editing tool CRISPR/Cas9, researchers have reprogrammed mutated rod photoreceptors to become functioning cone photoreceptors, reversing cellular degeneration and restoring visual function in two mouse models of retinitis pigmentosa. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 21, 2017 Category: Science Source Type: news

Using CRISPR to reverse retinitis pigmentosa and restore visual function
(University of California - San Diego) Using the gene-editing tool CRISPR/Cas9, researchers at University of California San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health, with colleagues in China, have reprogrammed mutated rod photoreceptors to become functioning cone photoreceptors, reversing cellular degeneration and restoring visual function in two mouse models of retinitis pigmentosa. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 21, 2017 Category: Biology Source Type: news

7 medtech stories we missed this week: April 14, 2017
[Image from unsplash.com]From FDA approvals to business expansion plans, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. BioTelemetry launches offer to acquire LifeWatch BioTelemetry and LifeWatch announced in an April 9 press release that the 2 companies have entered a transaction agreement that states BioTelemetry will launch a tender offer to acquire all shares of LifeWatch. The LifeWatch shareholders will receive either 10 Swiss francs in cash and 0.1457 shares of BioTelemetry stock per LifeWatch share or 8 Swiss francs in cash and 0.2175 shares of BioTelemetry stock per ...
Source: Mass Device - April 14, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Acelity BioTelemetry CollPlant LifeWatch MedTech Second Sight Sight Science Toshiba Medical Source Type: news

Terumo taps DeRyke as CV CEO | Personnel Moves – April 7, 2017
Terumo Corp. (TYO:4543) said yesterday it tapped Rob DeRyke as its new CV group prez & CEO, effective April 1, 2017, succeeding a retiring Mark Sutter. Prior to his appointment, DeRyke operated as Terumo CV group electromechanical systems division prez, the company said. “Under his leadership, Rob brought stability and improved profitability to the business,” Terumo Corp prez & CEO Shinjiro Sato said in a press release. DeRyke joined Terumo in 2012 as corporate quality VP, and has 25 years of experience in med device and pharmaceuticals, the company said. He has previously held positions at Ba...
Source: Mass Device - April 7, 2017 Category: Medical Equipment Authors: MassDevice staff Tags: Business/Financial News Active Implants AdvaMed Alphatec Holdings Inc. Anika Therapeutics Inc. Apollo Endosurgery Aurora Spine Baxter Biocorp Biogen Idec Biolase Technology Inc Bioventus LLC Bonesupport Clal Biotech Delcath Sys Source Type: news

Chinese backers put $18m into Bionic Vision Technologies
A pair of Chinese backers put $18 million into Bionic Vision Technologies and its retinal implant for blindness, the Australian company said today. Hong Kong-based China Huarong International Holdings and State Path Capital ponied up A$23.5 million, BVT said, noting that it plans to use the cash to build devices and launch clinical trials in retinitis pigmentosa, based on a 3-patient study using a prototype. The company developed the device using A$50 million (about $38.3 million) from a 5-year Special Research Initiative grant via the Australian Research Council. Existing backers include the Unive...
Source: Mass Device - April 3, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Funding Roundup Optical/Ophthalmic Wall Street Beat Bionic Vision Technologies Source Type: news

Is this artificial retina implant going to restore vision for millions of people?
(Natural News) Retinitis pigmentosa refers to a group of conditions in which the photoreceptors of the retina and the pigment epithelium under the photoreceptors are damaged. The condition is progressive and often runs in families. It is also the leading cause of blindness specifically caused by retinal degeneration. Vision problems usually start revealing themselves in... (Source: NaturalNews.com)
Source: NaturalNews.com - March 25, 2017 Category: Consumer Health News Source Type: news

6 visual impairment breakthroughs you need to know
[Image courtesy unsplash.com]About 285 million people have some form of visual impairment in the world, according to the World Health Organization. Of that number, 39 million are considered blind, and 246 million have low vision. Three-fifths of all vision impairment can be prevented or cured. Uncorrected refractive errors are one of the main causes of vision impairment in the world. There has been a host of recent breakthroughs, however, that offer hope for the visually impaired. There’s a smart watch that relays smartphone notifications using braille and retinal prosthetics that could restore sight. Here ...
Source: Mass Device - March 22, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Biotech Clinical Trials Implants Optical/Ophthalmic Prosthetics Research & Development blindness eSight Corporation gene therapy Keratonconus MedTech Nanovision Biosciences retinitis pigmentosa University of California San Diego Source Type: news

Genetic engineering prevents retinal cell loss in mice
Silencing a gene called Nrl in mice slowed degenerative diseases of the retina. The findings could lead to ways to prevent vision loss from diseases such as retinitis pigmentosa. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - March 20, 2017 Category: Consumer Health News Source Type: news

NightstaRx initiates Phase I/II trial of AAV-XLRPGR therapy to treat XLRP
UK-based biopharmaceutical company NightstaRx (Nightstar) has initiated enrolment and dosing in a Phase I/II clinical trial of its gene therapy 'AAV- XLRPGR' for the treatment of patients with X-linked retinitis pigmentosa (XLRP). (Source: Drug Development Technology)
Source: Drug Development Technology - March 20, 2017 Category: Pharmaceuticals Source Type: news

NIH scientists deploy CRISPR to preserve photoreceptors in mice
Silencing a gene calledNrlin mice prevents the loss of cells from degenerative diseases of the retina, according to a new study. The findings could lead to novel therapies for preventing vision loss from human diseases such as retinitis pigmentosa. The study was conducted by researchers at the National Eye Institute (NEI), part of the National Institutes of Health, and was published online today in Nature Communications.     (Source: News from NEI)
Source: News from NEI - March 14, 2017 Category: Opthalmology Authors: balintfyj Source Type: news

Volker Busskamp receives prize for application-oriented neurobiological research
(Goethe University Frankfurt) The young researcher has been awarded for his contribution to a gene therapy approach to treat retinitis pigmentosa and for the development of artificial neuronal circuits. Retinitis pigmentosa is an inherited eye disease that leads to blindness. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 14, 2017 Category: Biology Source Type: news

Breast cancer drug dampens immune response, protecting light-sensing cells of the eye
The breast cancer drug tamoxifen appears to protect light-sensitive cells in the eye from degeneration, according to a new study in mice. The drug prevented immune cells from removing injured photoreceptors, the light-sensitive cells of the retina in the back of the eye. The study, recently reported in theJournal of Neuroscience, suggests tamoxifen might work for the treatment of age-related macular degeneration (AMD) and retinitis pigmentosa (RP), blinding diseases that lack good treatment options. (Source: News from NEI)
Source: News from NEI - March 13, 2017 Category: Opthalmology Authors: balintfyj Source Type: news

Second Sight Medical  closes $20m rights offering
Second Sight Medical (NSDQ:EYES) said today it closed a previously announced rights offering, retaining approximately $20.1 million with proceeds slated to support development and improvement of its Argus II retinal prosthesis. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. In the oversubscribed round, Sylmar, Calif.-based offered non-transferable subscription rights to purchase units composed of a share of Second Sight common...
Source: Mass Device - March 9, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

7 medtech stories we missed: Feb. 17, 2017
[Image from unsplash.com]Several companies released diabetes study results this week, while companies like BioTime closed on their public offerings and Pixium implanted its first bionic eye. Here are 7 medtech stories we missed this week, but were still worth mentioning. 1. Insulet touts glucose control study Insulet Corp. announced the results from its first feasibility study of its Omnipod Horizon hybrid closed-loop system in a Feb. 17 news release. The positive results showed that the glucose control algorithm performed well and was safe to used day and night for adults who have type 1 diabetes. It also s...
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Business/Financial News Diabetes Food & Drug Administration (FDA) BioTime FlowAid Medical Technologies Insulet Corporation Medtronic Pixium Vision Polyganics Tandem Diabetes Care Valeritas Holdings Source Type: news

Pixium logs German reimbursement win for Iris II ‘ bionic eye ’
Pixium Vision (EPA:PIX) said today that its Iris II ‘bionic eye’ won NUB 1 reimbursement status from the German Institute for the Hospital Remuneration System. The company’s epi-retinal implant has 150 electrodes and a bio-inspired camera intended for patients who have lost sight due to retinitis pigmentosa. A computer processes images captured by the camera and transmits the data into a signal, which is then transferred back and projected onto an intraocular implant. The incoming signal stimulates the optic nerve and generates images that the brain can interpret as visual signals. This status i...
Source: Mass Device - February 14, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Implants Optical/Ophthalmic Prosthetics Wall Street Beat Pixium Vision Source Type: news

Second Sight announces upcoming rights offering
Second Sight Medical (NSDQ:EYES) today released information on an upcoming rights offering, with plans to open on February 10, with proceeds slated to support development and improvement of its Argus II retinal prosthesis. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. In the round, Sylmar, Calif.-based will offer non-transferable subscription rights to purchase units composed of a share of Second Sight common stock and a 5-ye...
Source: Mass Device - February 6, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

Second Sight wins German reimbursement for Argus II retinal prosthesis
Second Sight Medical (NSDQ:EYES) said today it won reimbursement coverage for its Argus II epiretinal prosthesis from the German Institute for the Hospital Renumeration System, covering 15 hospitals in the group’s NUB1 innovation program. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. The decision will allow approved hospitals to negotiate reimbursement for treating patients with advanced stage retinitis pigmentosa ...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

Second Sight Medical wins U.K. reimbursement nod for Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today that the U.K.’s National Health Service granted reimbursement for the company’s Argus II retinal prosthesis system for blind patients with retinitis pigmentosa. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the company said. The U.K.’s NHS said that “a selective group of severely blind patients with Retinits Pigementosa can have access to the Argus II,” according to Second Si...
Source: Mass Device - December 22, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news

NHS to fund pioneering bionic eye surgery
Electronic implants will restore some vision to patients with retinitis pigmentosa, an inherited eye disease (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 22, 2016 Category: Pharmaceuticals Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 7, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. First patient receives Pixium bionic vision implant Pixium Vision said today that the 1st patient in the UK was implanted with its IRIS II bionic vision system. The epi-retinal implant has 150 electrodes and a bio-inspired came...
Source: Mass Device - November 7, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news